{"entity":{"id":"stk-012","kind":"drug","name":"STK-012","aka":[],"tldr":"STK-012 is an experimental engineered immune-signalling protein from Synthekine, in phase 2 trials for non-small cell lung cancer.","summary":"STK-012 is an engineered cytokine (interleukin-2 partial agonist) from Synthekine. An alpha/beta-biased interleukin-2 partial agonist that preferentially stimulates antigen-activated T cells carrying the high-affinity IL-2 receptor, which includes CD25 (IL-2 receptor alpha) and IL2RB. The phase 2 part of NCT05098132 is in first-line PD-L1-negative non-squamous non-small cell lung cancer, with pembrolizumab, pemetrexed and carboplatin.","status":"phase-2","asOf":"2026-11-04","links":[{"label":"Synthekine pipeline","url":"https://www.synthekine.com/our-pipeline/"},{"label":"ClinicalTrials.gov NCT05098132","url":"https://clinicaltrials.gov/study/NCT05098132"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":["cd25","il2rb"],"drugs":[],"companies":["synthekine"],"institutions":[],"pathways":[],"terms":[],"trials":["nct05098132"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo startup monitors, investor portfolios (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-04"},"code":"STK-012","modality":"Engineered cytokine (interleukin-2 partial agonist)","mechanism":"An alpha/beta-biased interleukin-2 partial agonist that preferentially stimulates antigen-activated T cells carrying the high-affinity IL-2 receptor, which includes CD25 (IL-2 receptor alpha) and IL2RB.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/stk-012/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"target":[{"id":"cd25","kind":"target","name":"CD25 (IL-2 receptor alpha)","route":"/targets/cd25/"},{"id":"il2rb","kind":"target","name":"IL2RB","route":"/targets/il2rb/"}],"company":[{"id":"synthekine","kind":"company","name":"Synthekine","route":"/companies/synthekine/"}],"trial":[{"id":"nct05098132","kind":"trial","name":"Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers","route":"/trials/nct05098132/"}]}}